theeve appeal the gyn￿CologlCal cancers charity Gynaecology Cancer Research Fund Annual Report and Accounts for the year ended 31 December 2024 Company Reglstratlon Number: 04370087 Reglstered Charlty Number (England and Wales): 1091708 Reglstered Charlty Number (Scotland): SC042612 Gynaecology Cancer Research FurKI Annual Report Incorporallng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 Contents Legal and Admlnlstratlve Informatlon........................................................................................................... From the Chlef Executlve and Chalr of the Board of Trustees................................................................ Towards 2030 - Fast Fo￿ard Preventlon............................ ..................................................................... Goals 2025.....................................................................................................,...,............................................... Objectlves and ActlvStles,...,.,.,.,...,.,.,.,.,.,.,.,.,.............................................................................,.,.........,..,..... Alms and Vlslon.................................,.,..........,.,.,.,.,,.,..,,.,..,...,...,.,.,.,.,....,.......................................................10 Achlevements and Performance..,.,.,.,.,..,.,.,.,........ ........................................................,...,........,.,.,..,,..,....10 Structure, Governance and Management....,.,.,.,.....,.,............,.....,.,.....,...,................................................ 21 Flnanclal Revlew 2024,... . .25 Statement of Trustees, Responslbllltles.......,.,.,.,.....,.,.,.,...,............,............. Independent Audltor's Report to the Trustees of Gynaecology Cancer Research Fund ............... 28 Consolldated Statement of Flnanclal Actlvltles (Incorporatlng an Income and expendlture account) for the year ended 31 December 2024..............,.,.,.................................................................. 33 Consolldated and Charlty Balance Sheet as at 31 December 2024.,.....,........................................... 34 Consolldated Statement of Cash Flows for the year ended 31 December 2024............................. 35 Notes to the Fln8nclal Statements......................................................,.,......,....,.,.,..................................... 36 .26 Gynaecology ￿Cer Research Fund Annual Rewt Incorpor8tlng a Dlwect¢Ms' Report and Attw you tr•at p•tl•nts and lamlll•s, and your oryanlmtlon ar• very fortun•t• to h•v• Such a wond•rful Nur•• Coordlnator. Thank you •g•ln. You h•v• h•lp•d m• and my daught•r wh•n w• n••d•d It. and I wlll b• for•v•r grat•ful. 66 Ask Eve Is meetlng the needs of Its users at a tlme when servlce demand Is the hlghest It has ever been. The Implementation of our Al tool and volunteer support wlll enable the contlnued dellvery of a hlgh quallty, accesslble and Incluslve seNlce. reachlng and meetlng the needs of as many people as posslble whllst contlnulng to demonstrate Impact. We are grateful to everyone who supports Ask Eve and contrlbutes to fts development and success. The added value of Ask Eve Is summed up by one of our users: Nothlng but pr41•• •nd th4nks ft4r th• a¢e•Mlblllty to a v•ry Inlormatlv• and v•luabl• ￿r¥I¢• that could •av• or chang• p•opl•'• Ilv•g. Structure, Governance and Management Organlmtlonal •tructur• and deCI￿On maklng The Charlty Is governed by a Board of Trustees who are members and also dlrectors of the Charlty for the purposes of the Companles Act. The Board sets the strateglc dSrectlon of the Charlty, ensurlng that the charltable purposes of the Charlty are met. Day-to-day runnlng of the Charlty Is delegated by the Board to the Chlef Executlve Officer. The Eve Appeal conslders each of the Trustees to be Independent In character and Judgement and understands that they have no relatlonshlps that are Ilkely to affect. or could appear to affec( thelr Judgements wlth regard to the Charlty. Declaratlons of Interest are requlred from new Trustees upon appolntment and every meetlng of the Board requlres that any new Interests are declared. No remuneratlon Is provlded except for reasonable travel and subslstence costs; In 2024 thls flgure was £0. There are two Commlttees whlch make recommendatlons to the Board: the Flnance & Audlt Commlttee and the Research Commlttee. The purpose of the Flnance & Audlt Commlttee Is to ensure that a strateglc approach Is taken In the areas of flnance, rlsk, audlt, remuneratlon and other operatlonal areas. The Finance & Audlt Commlttee Is comprlsed of at least four members. all of whom are Trustees, who glve detailed conslderatlon, on behalf of the Board, to these matters. The Research Commlttee provldes scientific research advlce and works on the recommendatlons of the external Research Advisory Committee for new funding decisions. These recommendatlons are viewed in light of the charity's mission. charitable objectives and financial posltlon. and the commlttee makes recommendatlons and provides advlce to the Board of Trustees. The Charlty had one 100% owned subsidiary company In the year. Eve Appeal Llmlted Ss a tradlng company that distributes its profrts under Glft Aid to the Charty. 21 Gynoecology Cancer Research Fund Annual Report Incorporallng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 In 2021. in recognition of the Charity's support for key support programmes. the Prlnclpal Investlgator. Professor Martln Wldschwendter. gifted The Eve Appeal shares In a company. Sola Dlagnostlcs GMBH. whlch wlll be taking forward Innovatlve dlagnostlc tests whlch are at an early stage of development Any proflts arlslng from the venture wlll be fed back Into academlc medlcal research programmes. In 2023 Sola Dlagnostlcs GMBH had yet to make a profiL Truste• app•lnlment, Inductlon and tralnlng Trustees are appolnted In accordance wlth the Memorandum and Artlcles of Assoclatlon, taklng Into account the benefrts of appointing a person who Is able. by virtue of his or her personal or professlonal qualifications and experience. to make a contrlbutlon to the pursult of the objects or the management of the Charity. Trustees and staff conslder the skllls gaps formed by departlng Trustees and both openly advertlse for and nomlnate approprlate Indlvlduals wlth skllls to match before recommendatlon to Board for appolntment. References are taken before appolntment Ss formallsed and prospectlve Trustees are then proposed and appointed at the AGM. The Charlty undertakes a comprehensive Inductlon programme for all new Trustees, whlch Includes Inductlon materlals relatlng to its purposes and flnances, the powers and dutles of the Trustees and Informatlon about day-to-day runnlng of The Eve Appeal. Key documents are provlded, such as the Memorandum and Artlcles of Assoclatlon, the Charlty Commlsslon's Essentlal Trustee gulde, up-to- date accounts, and mlnutes of the most recent Trustee meetlngs. Prospectfve Trustees may also attend relevant Trustee meetlngs as an observer as part of the Inductlon process alongslde Introductlons to key people and places. Trustees contlnue to be supported through ongolng tralnlng, wlth sk1115 requlrements regularly revlewed. The Tru•t••s who Serv￿ In th• p•rlod under r•vl•w w•rv. Melanle Rlchards CBE {Chalr of Trustees) (Reslgned, 07102124) Tamara Box (Appolnted 0110712020) (Chalr of Trustees effectlve 0810212024) (Appolnted 0411112019) (Reslgned 0510212025) (Appolnted 2611012020) (Appolnted 2910512022) (Reslgned 25101124) (Appointed 1911212019) (Appolnted 2711012021) (Appolnted 0411112019) (Appolnted 2611012020) (Appolnted 1811012023) (Reslgned 2310112025) (Appolnted 1811012023) (Appointed 0510212025) Sarah Clark lan Drew Dr Chrlstlne Ekechl Prof lan Jacobs Sldonle Klngsmlll Sarah Morris Marlon O'Hara Cathy Plttham-wlley Prof Adam Rosenthal Sally Balley Dee Brecker Emma Dean Helen Byrne Declaratlon of Interests All Trustees and staff are requlred to declare thelr Interests, and any payments (Includlng, but not Ilmlted to. beneflts In klnd such as glfts. hospltallty shopplnghravel concessions. preferential treatment, etc) recelved In connection with their role In The Eve Appeal where such Interests would. or mlght. confllct wlth, or Otherwo￿ Influence thelr declslon-maklng In respect of the Charlty's activities. 22 Gynaecology Cancer Research Fund Annual Report Incorporallng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 Wlth thanks to all members of the Research Advlsory Committee: Nam• Occupatlon and Oryanlsatlon Date of appolntment Professor Emma Crosble (Chair) Professor of Gynaecologlcal Oncology Manchester Unlversty Lead Gynae Oncology Cllnlcal Nurse Speclallst Royal Devon Unlverslty Healthcare Trust Lay/Communlty Representatlve Laylcommunlty Representatlve January 2024 Mrs Rhea Crlghton January 2021 Dr Helen Howle January 2021 Professor Sudha Sundar Professor of Gynaecologlcal Cancer, Unlverslty of Blrmlngham Emerltus Professor of Women's Cancer Professor Anne Lanceley Care, Instltute for Women's Health, Unlverslty College London Senlor Lecturer, Prlmary Care Cancer Research, Woltson Instltute of Populatlon Health, Queen Mary Unlverslty of London Honorary Profe55or, Instltute of Cancer and Genomlc Sclences, Blrmlngham Unlverslty; Consultsnt Gynaecologlcal Pathologlst Professor of Ovarlan Cancer Medlclne In the Professor James Brenton Department of Oncology, Unlverslty of Cambrldge June 2019 June 2024 Dr Garth Fun5ton June 2024 Professor Rajl Ganesan June 2024 May 2025 Staff A Senlor Management Team comprlslng the Chlef Executlve, the Dlrector of Fundralslng, the Head of Flnance and Head of Programmes allows for dlstrlbutlon of organlsatlonal responslblllty and both staff and Trustees contlnue to be happy wlth the structure. The CEO h85 partlcular responslblllty for Issues relatlng to governance and for the flnanclal management of the organlsatlon. The Eve Appeal has 20 permanent members of staff and the Trustees record thelr appreclatlon of the efforts of the staff. who have agaln made an enormous contributlon to the success of The Eve Appeal and Its mlsslon durlng the year. Volunts•rs and Advocat Volunteers and advocates play an essentlal role In shaplng and drlvlng The Eve Appeal's mlsslon. They share thelr personal experlences, support our research, revlew our health Informatlon, engage wlth the medla. support fundralslng and act as medlcal advocates across a range of activity. Their contributions ensure that our work remalns patlent-centred, impactful and far- reachlng. As we grow. we are committed to fostering a more structured and Incluslve approach to volunteer engagement, recognising the vital role that Eve Voices play across our research. awareness and outreach efforts. By embedding meaningful involvement Into our work, we aim to bulld a strong. empowered network that contributes to research, health education and advocacy in a way that benefits both the charty and those involved. 23 Gynaecol¢)gy Cancer Research Fund Amuol Report Incorporallng a Dlreclors, Report and Accounts for the year endlng 31 December 2024 We are hugely proud of our rnany advocates and thelr pass5on and engagement In the charlty. We are also proud of our support of these volunteers to date and the close communlty that we have fostered. We are working to build on this strong foundation and develop clear frameworks to support. traln and recognlse our volunteers. ensurlng that their time and expertlse are valued. By strengthenlng our systems for engagement and Impact measurement. we wlll contlnue to bulld a charlty that not only listens to Its communlty but thrlves because of ft. Our volunteers and dvocates are the heart of our work. and thelr volces wlll shape the future of gynaecologlcal cancer preventlon and early detectlon. Equlty, Dlv•rslty and In¢lu•lon Equallty. dlverslty and Incluslon Is at the heart of everythlng we do. Gynaecologlcal cancers can have a negatfve Impact on anyone's Ilfe. That's why we make sure our research, educatlonal campalgns and free. expert Informatlon and advlce are focused on helplng everyone who could be affected by a gynaecologlcal cancer. We want to prevent every slngle case of gynaecologlcal cancer posslble. To do that we know that addresslng health Inequalltles Is central to our mlsslon. We work wlth dlverse communftles across the UK to ralse awareness of gynaecologlcal cancers. to gulde our research projects and our pollcy dlscusslons. We're unwaverlng In our commltment to foster an envlronment where equlty Is promoted. dlverslty Is valued and celebrated, and everyone feels Included. We're gulded by our values and contlnuously learn and adapt to ensure EDI Is embedded In everythlng we do. We Invlte 811 our partners, suppllers and supporters to Joln u5 In thls work. Saf•guardlng Pollcy All staff and Trustees have been offered tralnlng. We have a safeguardlng le8d Trustee and a clear escalatlon process In place. Safeguardlng Issues and concerns are notlfled to the Board as part of the quarterly reportlng process. The Eve Appeal Is commltted to valulng dlverslty, preventlng dlscrlmlnatlon and achlevlng equallty of opportunlty. The Eve Appe81 belleves everyone has the rlght to Ilve free from abuse or neglect regardless of age, ablllty or dlsablllty, sex, race, rellglon, ethnlc orlgln, sexual orlentatlon. marltal or gender status. The Eve Appeal wlll not dlscrlmlnate on the grounds of domestlc clrcumstsnces, educatlonal or soclal-economlc status. polltlcal affillatlon, or trade union membershlp. The Eve Appeal Is commltted to creatlng and malntalnlng a safe and posltlve envlronment and an open. Ilstenlng culture where people feel able to share concerns wlthout fear of retrlbutlon. The Eve Appeal acknowledges that safeguardlng Is everybody's responslblllty and Is commltted to preventlng abuse and neglect through safeguardlng the welfare of all adults Involved. The Eve Appeal recognises that health. well-being, abillty. dlsabillty and need for care and support can affect a person's reslllence. We recognlse that some people experience barriers. for example. to communication in raislng concerns or seeklng help. We recognlse that these factors can vary at dlfferent points In people's Ilves. Safeguarding actions taken by The Eve Appeal wlll be conslstent with the prlnclples of adult safeguarding ensurlng that any action taken Is prompt. proportlonate and that It includes and respects the voice of the adult concerned. 24 Gynaecology Cancer Resewch Fund Annual Report Incorporadng a Dlrectors. Report and Accounts f¢x the year endlng 31 Oecernber 2024 Flnanclal Revlew 2024 Transactlons and Flnanclal Posltlon At December 2024 year end. we reported a surplus of £470.402 (2023: £362.326) in unrestricted reserves to carry forward Into 2025. Thls surplus comprlses funds of £290.402 above our agreed operating reserves level of £180.000. In 2023 we Introduced a Research Fellowshlps Programme, supportlng our legacy programme wlth Prof. Martln Wldschwendter, as well as holdlng a research open call. We have an ambltlous programme for 2025 grant awards. Endlng 2024 wlth substantlal unrestrlcted reseNes places The Eve Appeal In a posltlon to meet our award ambltlons. In summary, we begln 2025 In a cautlous but stsble posltlon wlth £470,402 In unrestrlcted funds. Thls leaves £290,402 In free reseNes. Free reserves are the unrestrlcted funds balance mlnus the operatlng reserves level of £180,000. At end of 2024 overall cash balance was £1,060,129. Fundlng Fundralslng pollcy Sectlon 162a of the Charltles Act 2011 requlres charltles to make a statement regardlng fundralslng actlvltles. The leglslatlon defines fundralslng as 'sollcltlng or otherwlse procurlng money or other property for charltable purposes.. Such amounts recelvable are presented In our accounts as 'donatlons and voluntary Income,. We conflrm that all sollcltatlons are managed Internally. wlthout Involvement of commerclal partlclpators or professlonal fundralsers or thlrd partles. The day-to-day management of all Income generatlon Is delegated to the executlve team, whlch Is accountable to the Trustees. We have recelved no complalnts In relatlon to fundralslng actlvltles. The Eve Appeal Is funded prlnclpally by voluntary donatlons from Indlvldu81s and communlty groups who contlnue to support our work and mlsslon. Corporate sponsorshlp and donatlons also ccount for a slgnlflcant proportlon of our fundlng. Wlthout thls support we would not be able to operate and we are Incredlbly grateful for every penny that Is donated. Rlsk Management The Trustees have assessed the major rlsks to whlch The Eve Appeal Is exposed and are satlsfied that systerns are estsbllshed to mltlgate the Charlty's exposure to those rlsks. These rlsks are detalled on the Rlsk Reglster for The Eve Appeal. wlth Informatlon on the current practlce and strategy used to mltlgate the rlsk. The Register Is revlewed quarterty by Trustees. The current Rlsk Reglster pays partlcular attentlon to the rlsks around the current fundralslng envlronment and the on-golng economlc crlses on Income and operatlons, research not reachlng Intended objectlves. fundralslng targets belng mlssed, loss of key Indlvlduals. IT fallure (Includlng cyber securlty rlsk) and incorrect information being provided on a health issue. The Integrlty of medlc81 Informatlon provlded by the Charlty Is managed by agreed peer-revlewed protocols, wlth Informatlon standards applled across all materlals and channels. A balanced portfollo of fundralslng actlvlty spreads rlsk to reduce any potentlal Impact. Regular flnanclal plannlng, Includlng re-forecast of fundraising Income and expendlture. ensures early Interventlons can be made. 25 Gynaecolopy Cancer Research Fund AMU81 Report Incorporatlng a Dlrectors. Rewt and Accounts for the year endlng 31 December 2024 R•8•ms Pollcy The 2024 annual revlew of the reserves pollcy determlned that no adjustments was required to the figure set In 2023 of £180,000. The figure Is set by the Board as a target of holding £180,000 In free reserves. Thls tsrget Is based on the contingency for wind up finds, calculated to satisfy all the Charity liabilities In the event of closure. In real terms. £180,000 represents just under three months, budgeted expenditure, excluding expenditure on research grants and restricted charitable activities. We begin 2025 in a cautious but stable position wlth £470,402 In unrestrlcted funds. Thls leaves £290,402 In free reseNes which Is in addltion to operatlng reserve level of £180.000. The Board wlll contlnue to revlew the reserves pollcy annually to ensure It remalns approprlate to the needs of the Charlty In the context of the economlc cllmate. Oolng Con¢•rn The Trustees have revlewed the Charlty's flnanclal posltlon, taklng Into account the levels of reserves, cash, commltted Income Included In the accounts, future plans and Its systems of flnanclal and rlsk management. The Trustees belleve that the Charlty Is well placed to manage operatlonal and flnanclal rlsks successfully. Accordlngly, the Trustees have a reasonable expectatlon th8t the Ch8rlty has adequate resources to contlnue In operatlon for the foreseeable future and conslder that there are no materlal uncertalntles about the group's ablllty to contlnue as a golng concern. Or•nt M•klng Polky The pollcy of the Trustees Is to fund world-class medlcal research that wlll make the blggest Impact In savlng women's Ilves from gynaecologlcal cancers, Includlng fundlng proof-of-prlnclple work to enable the award of future fundlng. As a member of the Assoclatlon of Medlcal Research Charltles, we have developed 8 Strategy and fundlng declslon-maklng processes that meet strlct awardlng crlterla and revlew, and recommendatlons are made by Independent experts In the research fleld. ststement of Trustees, Responslbllltles The Trustees (who are 8150 dlrectors of Gynaecology Cancer Research Fund for the purposes of company lawl are responslble for preparlng the Trustees, Report and the flnanclal statements In accordance wlth appllcable law and Unlted Klngdom Accountlng Stsndards (Unlted Klngdom Generally Accepted Accountlng Practlce). Company and charlty law requlres the Trustees to prepare flnanclal statements for each flnanclal year. Under company law the Trustees must not approve the flnanclal statements unless they are satlsfled that they glve a true and falr vlew of the state of affalrs of the charltable company and the group and of the incoming resources and applicatlon of resources. Includlng the Income and expendlture, of the charltable group for that period. In preparlng these flnanclal statements. the Trustees are required to: select sultable accountlng pollcles and appty them conslstently; observe the methods and prlnclples In the Charftles SORP (FRS 102); make Judgements and estimates that are reasonable and prudent; 26 Annual Report Incorporallng a DlrecioryJ' Report and AcCo￿ts for the year endlng 31 December 2024 state whether appllcable UK Accountlng Stsndards have been followed. subject to any material departures disclosed and explalned In the financlal statemerrts: prepare the financlal statements on the golng concern basls unless It Is Inapproprlate to presume that the charitsble company will continue in buslness. The Trustees are responsible for keeping adequate and proper accounting records that are sufficlent to show and explain the charltable company's transactions and dlsclose with reasonable accuracy at any time the financial positlon of the charltable company and enable them to ensure that the flnanclal statements comply wlth the Companles Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charltles Accounts (Scotland) Regulatlons 2006 (as amended). They are also responslble for safeguardlng the assets of the charitsble company and the group and hence for tsklng reasonable steps for the preventlon and detectlon of fraud and other Irregularltles. In so far as the Trustees are aware: there Is no relevant audlt Informatlon of whlch the charltable compary's audltor Is unaware: the Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audlt Informatlon and to estsbllsh that the audltor Is aware of that Informatlon. The Trustees are responslble for the malntenance and Integrlty of the corporate and financlal Informatlon Included on the charltable company's webslte. Leglslatlon In the Unlted Klngdom governlng the preparatlon and dlssemlnatlon of financlal statements may dlffer from leglslatlon In other Jurlsdlctlons. Thls report has been prepared In accordance wlth the speclal provlslons relatlng to small companles wlt n Part 15 of the Companles Act 2006. If of the ar Tam Box. Chalr iYIDsI Date.. 27 Gynaecology Cancer Research Fund Annual Report Incorwatlng a Dlrectors. Report and Accounts for the yew endlng 31 December 2024 Independent Audltor's Report to the Trustees of Gynaecology Cancer Research Fund Oplnlon We have audlted the financlal statements of Gynaecology Cancer Research Fund ('the parent charltable company,) and its subsidiaries (the 'group') for the year ended 31 December 2024 whlch comprise the Group Statement of Financial Actlvities (including the Group Summary Income and Expendlture Account), the Group and Parent Charitable Company Balance Sheets, the Group Cash Flow Statement and notes to the flnancial statements, including significant accountlng pollcles. The flnanclal reportlng framework that has been applled In thelr preparatlon Is applicable law and Untted Klngdom Accountlng Standards, Including FRS 102 'The Flnanclal Reportlng Standard Appllcable In the UK and Republlc of Ireland, (Unlted Klngdom Generally Accepted Accountlng Practlce). In our oplnlon the financial ststements: glve a true and falr vlew of the state of the group's and the parent charltable company's affalrs as at 31 December 2024 and of the group's Incomlng resources and appllcatlon of resources, IncludSng Sts Income and expendlture, for the year then ended; have been property prepared In accordance wlth Unlted Klngdom Generally Accepted Accountlng Practlce; and have been prepared In accordance wlth the requlrements of the Companles Act 2006, the Charltles and Trustee Investment (Scotland) Act 2005 {as amended), regulatlons 6 and 8 of the Charltles Accounts (Scotland Regulatlons 2006 (as amended) and the Charltles Act 2011. Ba￿• for oplnlon We conducted our audlt In accordance wlth Internatlonal Standards on Audltlng (UK) (ISAS (UK)) and appllcable law. Our responslbllltles under those standards are further descrlbed In the Audltor's Responslbllltles for the audlt of the flnanclal statements sectlon of our report. We are Independent of the charltable company In accordance wlth the ethlcal requlrements that are relevant to our audtt of the fln8ncS8l statements In the UK, Includlng the FRC'S EthScal Standard, and we have fulfllled our other ethlc81 responslbSlltles In accordance wlth these requlrements. We belleve that the audlt evldence we have obtalned Is sufflclent and approprlate to provlde a b8sSs for our oplnlon. Conclu8lons relatlng to golng concern In audlting the financial statements, we have concluded that the trustees, use of the golng concern b851s of accountlng In the preparatlon of the flnanclal statements Is approprlate. Based on the work we have performed, we have not Identlfied any materlal uncertalntles relating to events or conditlons that, Indlvldually or collectlvely. may cast slgnlflcant doubt on the charitable company's ability to continue as a going concern for a perlod of at least twelve months from when the financial statements are aLrthorlsed for Issue. Our responsibilities and the responsibilitles of the trustees wlth respect to golng Concern are descrlbed In the relevant sectlons of thls reporL Olh•r Infomiallon The other Information comprlses the Informatlon Included In the annual report, other than the flnanclal statements and our audltor's report thereon. The trustees are responsible for the other Information contalned withln the annual report. Our opinlon on the financlal statements does not cover the other Informatlon and. except to the extent otherwlse explicltty stated In our report. we do not express any form of assurance concluslon thereon. 28 Gynaecology Cancer Research Fund Annual Report Incorporallng a Dlrectors. Report and Accowts for the year endlng 31 December 2024 Our responslblllty Is to read the other informatlon and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtalned In the course of the audit or otherwise appears to be materially mlsstated. If we Identify such materlal Inconsistencies or apparent material misstatements, we are required to determlne whether there Is a material misstatement in the financial statements themselves. If. based on the work we have performed, we conclude that there is a material misstatement of this other Information, we are requlred to report that facL We have nothlng to report In thls regard. Oplnlon• on •ther matter• pr•Krlbed by the Compan1￿ Art 2006 In our oplnlon, based on the work undertaken In the course of the audlL' the Informatlon glven In the trustees. annual report for the financlal year for whlch the flnanclal statements are prepared Is conslstent wlth the financlal ststements; and trustees, annual report have been prepared In accordance wlth appllcable leg81 requlrements. Matter• on whl¢h w• ar• r•qulr•d to r•port by •xc•ptlon In the Ilght of the knowledge and understandlng of the company and Its envlronment obtalned In the course of the audlt, we have not SdentSfied materlal mlsstatement5 In the trustees. annual report. We have nothlng to report In respect of the followlng matters where the Companles Act 2006, the Charltles Accounts (Scotland) Regulatlons 2006 (as amended) and the Charltles Act 2001 requlres us to report to you If. In our oplnlon: adequate accountlng records have not been kept, or returns adequate for our audlt have not been recelved from branches not vlslted by us: or the flnanclal statements are not In agreement wlth the accountlng records and returns; or cert8ln dlsclosures of trustees, remuneratlon speclfled by law are not made; or we have not recelved all the Informatlon and explanatlons we requlre for our audlt; or the trustees were not entltled to prepare the flnanclal statements In accordance wlth the small companles reglme and take advantage of the small companles exemptlon In preparlng the tru5tees' annual report and from preparlng a strateglc report. R••pon•lbllttle• of tru•te•• As explalned more fully In the trustees, responslbllltles statement set out on page 27. the trustees {who are also the dlrectors of the charltable company for the purposes of company law) are responsible for the preparatlon of the financial statements and for belng satlsfied that they glve true and fair view, and for such internal control as the trustees determlne Is necessary to enable the preparatlon of flnanclal ststements that are free from materlal mlsstatement, whether due to fraud or error. In preparlng the flnanclal statements, the trustees are responslble for assesslng the charltable company's abillty to contlnue as a golng concern. dlscloslng, as applicable, matters related to going concern and uslng the golng concern basls of accounting unless the trustees elther Intend to Ilquldate the charltable company or to cease operatlons. or have no realistic alternative but to do so. Audltor's Responslbllltles for the audlt of the flnanclal statements We have been appolnted as audltor under Sectlon 4411)(c) of the Charitles and Trustee Investment {Scotland) Act 2005. the Companles Act 2006 and Sectlon 151 of the Charlties Act 2011 and report to you In accordance wlth regulatlons made under those Acts. 29 Gynoecology c￿cer Research Fund Annual Report Incorporatlng a Dlrectors. Report and ACCO￿ for the year endlng 31 December 2024 Our objectives are to obtain reasonable assurance about whether the financlal statemerrts as a whole are free from material mlsstatement, whether due to fraud or error. and to Issue an auditor's report that Includes our oplnlon. Reasonable assurance Is a hlgh level of assurance. but is not a guarantee that an audlt conducted in accordance wlth ISAS (UK) wlll always detect a material misstatement when It exlsts. Mlsstatements can arise from fraud or error and are considered materlal if. individually or in aggregate, they could reasonably be expected to Influence the economlc declslons of users taken on the basls of these financlal statements. As part of an audlt In accordance wlth ISAS (UK) we exerclse professlonal Judgement and malntaln professional scepticism throughoLrt the audit. We also: Identlfy and assess the rlsks of materlal mlsststement of the financlal statements, whether due to fraud or error, deslgn and perform audit procedures responslve to those rlsks, and obtaln audlt evldence that Is sufflclent and approprlate to provlde a basls for our oplnlon. The rlsk of not detectlng a materlal misstatement resultlng from fraud Is hlgher than for one resultlng from error, as fraud may Involve collusion, forgery, Intentlonal omlsslons. mlsrepresentatlons, or the overrlde of Internal control. Obtaln an understandlng of Internal control relevant to the audlt In order to deslgn audlt procedures that are approprlate In the clrcumstances, but not for the purposes of expre551ng an oplnlon on the effectlveness of the charltable company's Internal control. Evaluate the approprlateness of accountlng pollcles used and the reasonableness of accountlng estlmates and related dlsclosures made by the trustees, Conclude on the approprlateness of the trustees, use of the golng concern basls of accountlng and, based on the audlt evldence obtalned, whether a materlal uncertalnty exlsts related to events or condltlons that may cast slgnlflcant doubt on the charltable company's ablllty to contlnue as a golng concern. If we conclude that a materlal uncertalnty exlsts, we are requlred to draw attentlon In our audltor's report to the related dlsclosures In the flnanclal statements or, If such dlsclosures are Inadequate, to modlfy our oplnlon, Our concluslons are based on the audlt evldence obtalned up to the date of our audltor's report. However. future events or condltlons may cause the charltable company to cease to contlnue as a golng concern. Evaluate the overall presentatlon. structure and content of the flnanclal statements, Includlng the dlsclosures, and whether the flnanclal statements represent the undertylng transactlons and events In a manner that achleves falr presentatlon. Obtaln sufflclent approprlate audlt evldence regardlng the flnanclal Informatlon of the entltles or buslness actlvltles wlthln the group to express an oplnlon on the consolidated flnanclal statements. We are responslble for the dlrectlon. supervlslon and performance of the group audlt. We remaln solety responslble for our audft report. We communlcate wfth those charged wlth governance regardlng, among other matters, the planned scope and tlmlng of the audlt and significant audlt findlngs, Including any significant deflclencles In Internal control that we Identify during our audlt. Explanallon as to what •xt•nt th• audft was eonsld•r•d Capab￿ of d•t•ctlng Irregularltl• Includlng fraud Irregularities. including fraud. are instances of non-compllance w5th laws and regulatlons. We deslgn procedures In Ilne wlth our responslbilities. outlined above, to detect materlal mlsststementS in respect of Irregularltles, including fraud. The extent to wh5ch our procedures are capable of 30 Gynaecology Cancer Research Fund Annual Report Incowatlng a Dlrectors. Report and Attounts for the year endlng 31 December 2024 detectlng Irregularltles. Includlng fraud Is detslled below. The objectlves of our audlt In respect of fraud. are: to Identify and assess the risks of materlal misstatement of the financial statements due to fraud: to obtain sufflcient appropriate audlt evldence regardlng the assessed risks of materlal misstatement due to fraud. through designlng and implementing appropriate responses to those assessed iisks; and to respond appropriatety to Instances of fraud or suspected fraud Identlfied during the audlt. However, the prlmary responslblllty for the preventlon and detectlon of fraud rests wlth both management and those charged wlth governance of the charltable company. Our approach was as follows: We obt81ned an understsndlng of the legal and regulatory requlrements appllcable to the charltable company and consldered that the most slgnlficant are the Companles Act 2006, the Charltles and Trustee Investment (Scotland) Act 2005 (as amended), regulatlons 6 and 8 of the Ch8rStles Accounts (Scotland) Regulatlons 2006 (as amended), the Charltles Act 2011, the Charlty SORP, and UK flnanclal reportlng standards as Issued by the Flnanclal Reportlng Councll and UK tax leglslatlon. We obtalned an understandlng of how the charltable company complles wlth these requlrements by dlscussions with management and those charged wlth governance. We assessed the rlsk of materlal m155tatement of the flnanclal ststements. Includlng the rlsk of rnaterlal mlsstatement due to fraud and how It mlght occur, by holdlng dlscusslons wlth management and those charged wlth governance. We Inqulred of management and those charged wtth governance asto any known Instsnces of non-compllance or suspected non-compllance wlth laws and regulatlons. Based on thls understandlng, we deslgned speclfic approprlate audlt procedure5 to Identlfy Instances of non-compllance wlth laws and regulatlons, Thls Included maklng enqulrles of management and those charged wlth governance and obtalnlng addltlonal corroboratlve evldence as requlred. There are Inherent Ilmitatlons In the audlt procedures descrlbed above. We are less Ilkely to become aware of Instances of non-compllance wlth laws and regulatlons that are not closely related to events and transactions reflected In the flnanclal statements. Also, the risk of not detectlng a materlal mlsstatement due to fraud Is hlgher than the rlsk of not detectlng one resulting from error, as fraud may Involve dellberate concealment by, for example, forgery or Intentlonal mlsrepresentatlons, or through colluslon. of our r•port Thls report is made solely to the charltable company's members, as 8 body, In accordance wlth Chapter 3 of Part 16 of the Companles Act 2006; and to the Charty's Trustees. as a body In accordance wlth Sectlon 44(1)(c} of the Charltles and Trustee Investment {Scotland) Act 2005. and In respect of the consolldated flnanclal statements, In accordance wlth Chapter 3 part 8 of the Charities Act 2011. 31 Gynaecology Cancer Research Fund Annual Report Incorporaung a Dlrectors. Report and AcCo￿ts ts the year endlng 31 December 2024 Our audit work has been undertaken so that we mlght state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permltted by law. we do not accept or assume responsibility to any party other than the charitable company and charitable company's members as a body, for our audit work. for thls report. or for the oplnions we have formed. James Saunders. FCCA DCHA {Senlor Lrtory Audltor) for and on behalf of Moore Klngston Smlth LLP, Statutory Audltor 6th floor 9 Appold Street London EC3A 2AP Date: Moore Klngston Smlth LLP Is ellglble to act as audltor In terms of Sectlon 1212 of the Companles Act 2006. 32 Gynaecology Cancer Research Fund Annual Report Incorporallng a Dlrect¢yrs' Rep￿ and Accounts for the year endlng 31 December 2024 Consolldated Statement of Flnanclal Actlvltles (Incorporatlng an Income and expendlture account) for the year ended 31 December 2024 Notes Unrestrlcted Restrlcted 2024 2023 Income Don8tlons and legacles Other tradlng actlvltles Investment Income Other Income Total 1,231,010 101.550 22.702 427.576 1,658,586 101,550 22.702 1,241,205 87,901 15,474 278 427.576 1.782.838 1.344.858 1.355.262 Expendlture RaisSng fund Charltable actlvlty Total 584,374 662 812 1.247.186 84 584,458 594,756 434 984 1097 796 1,005,524 435.068 1.682,254 1,600.280 Net Incomelexpendlture 108,076 {7.492) 100,584 (255,422) Transfers between funds Net movement In funds 108,076 17,492) 100,584 (255,422) Reconclllatlon of funds Total funds brought forward 362,326 319,461 681,787 937,209 Total funds carrled forward 311969 782 371 681787 All the above amounts relate to contlnulng actlvltles. 33 Gynaecology Qncer R¢sear¢h Fund Annual Rewt Incorporatlng a Dlrectorf Report and Accounts for the year endlng 31 December 2024 Consolidated and Charity Balance Sheet as at 31 December 2024 Group Charity Notss 2024 2023 2024 2023 Flxed assets Intsngible flxed assets Tangible fixed assets Investment 14 15 16 2,662 10,607 3,461 17,981 2,662 10,607 3,461 17,981 20,700 28,873 20,701 28,874 Current assets Debtors Cash at bank and in hand 17 201,221 1060 129 1,261,350 191,025 928 895 1,119,920 157,861 1029 414 1,187,275 180,863 1,022,340 Creditors: amounts falllng due 467 006 455 056 Net current assets 761,671 652,914 657,180 567,284 Net Assets 782 371 681787 677 881 596 158 Funds Restrlcted Unrestrlcted Total Funds 20 19 311,969 470 402 782 371 319,461 362 326 681787 311,969 365 912 677 881 319,461 276 697 596 158 As pemiltted by S408 of the Companles Act 2006, the company has not presented its own Income and expenditure and related notes. These financial ststements were approved by the Board of Trustees and authorised for Issue on 14 May 2025 ar￿ were signed on its behalf by: Tamara Bo& Chalr Company No. 4370087 34 GyMecolo9y Cancer Researth FurKI Annual Report Incorporallng a Dlreclws, Report and Accourbts for the year endlng 31 December 2024 Consolldated Statement of Cash Flows for the year ended 31 December 2024 2024 2023 Cashflow from operatlng actlvltles Cash provlded by operatlng actlvftles 109,820 (151.812) Cash flows from Investlng actlvStSes Interest Income Purchase of tanglble flxed assets 22,702 (1,288) 15,474 (9,384 Net cash used In Investlng actlvltles 21.414 6.090 Change In cash and cash equlvalent In the perlod 131,234 928 895 1,060,129 <14S,722) 1074 607 928.885 st Cash and cash equlvalents at 1 January Cash and cash equlvalents at 31" December Reconclllatlon of net Incomelexpendlturel to net cash flow from operatlng actlvltles: Net Incomel(expendlture) for the perlod Adjustment for: Investment Income Depreclatlon Amortlsatlon Decreasel(IncTease) In stock Decreasel(Increase) In debtors (Decrease)Ilncrease In credltors 100,584 (255,422) (22,702) 8,662 799 (15,474) 3.564 799 250 95.406 19,065 (10.196) 32,673 Net cash provlded bylused In operatlng actlvttles 109.820 {151.812) Analysls of cash and cash equlvalent and net debts Cash In hand and at bank Openlng balance Cash flows 928,895 131.234 1,074,607 145,722 Closlng balance 1060 129 35 Gynaecology Cancer Research Fund Annual Report Incorporallng a Dlrectors. Report and Accounts for the year endlng 311)ecembef 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 1. GENERJL INFORMATK>N Company Informallon Gynaecology Cancer Research Fund, operatlng as The Eve Appeal, Is a publlc benefft entlty, a charlty registered In both England and Wales (reglstered charlty number 1091708) and Scotland (SC0462612), and a company Ilmlted by guarantee (company number 04370087). reglstered In England. The reglstered office and Its prlnclpal place of buslness Is The Eve Appeal, 10-18 Unlon Street, London, SE11SZ. 2. ACCOUNTING POLICIES (a) 8asl• ol pr•paratl¢ The flnanclal statements have been prepared under the hlstorlcal cost conventlon wlth Items recognlsed at cost or transactlon value unless otherwlse stated In the relevant note{s) to these fin8nclal statements. The financlal statements have been prep8red In accordance wlth the Accountlng and Reportlng by Charltles: Ststement of Recommended Practlce appllcable to Charltles preparlng thelr accounts In accordance wlth the Fln8nclal Reportlng Standard appllcable In the UK and Republlc of Ireland IFRS102) Includlng Update Bulletln 2, (Charltles SORP {FRS 102), the Flnanclal Reportlng Standard appllcable In the UK and Republlc of Ireland (FRS 102) and the Companles Act 2006. Gynaecology Cancer Research Fund constltutes a publlc beneflt entlty as deflned by FRS 102. The flnanclal statements are prepared In sterllng, whlch Is the functlonal currency of the company. Monetary amounts In these flnanclal statements are rounded to the nearest £1. The Trustees conslder that there are no materlal uncertalntles about the group's ablllty to contlnue as 8 golng concern. (b) Golng Concern The Tru5tee5 have assessed whether the use of golng concern Is approprlate and have consldered events or condttlons that mlght cast slgnlflcant doubt on the ablllty of the group to contlnue as a golng concern. The Trustees have gSven due conslderatlon to the current economlc uncertalnty and have reduced the rlsk wlth Income spread across dlfferent Stream of actlvlty. Havlng revlewed forecasts prepared by management the Trustees are confldent that the Charlty and the group wlll contlnue to meet Its obllgations as they fall due and that therefore the golng concern basls contlnues to be approprlate. 36 Gynaecology Cancer Resewch Fund Annual Report IncOrp￿￿tIng 8 Dlrectors. Report and Accounts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 ¢c> Group Flnanclal Statements These flnancial statements consolidate the results of the Charlty and Its wholly owned subsidiary, The Eve Appeal Limited, on a line-by-llne basis. The subsldiary company has the same year end date of 31 December 2024. (d> Fund Accountlng Unrestrlcted funds comprlse accumulated surpluses and deficlts on general funds. They are available for use at the dlscretlon of the Trustees In furtherance of the general charStsble objectlves. Deslgnated funds are unrestrlrted funds whlch are earmarked for a partlcular purpose. Restrlcted fund5 are funds subject to speclflc restrlctlons Imposed by the donors. l•) In¢om• Income represents amounts recelvable by the Charlty durlng the year from all sources. All Income Is Included In the Statement of Flnanclal Actlvltles when the charlty Is legally entltled to the Income and the amount can be quantlfled wlth reasonable accuracy. Legacles are accounted for when the Charlty has entltlement, recelpt Is probable. and the amount Is measurable, Donatlon5 are accounted for on a recelvable b8515. Other tradlng actlvltles are accounted for on a recelvable basls and In the year to whlch they relate. Donated servlces or facllltles are recognlsed when the Charlty has control over the Item, any condltSons assoclated wlth the donated Item have been met, the recelpt of economlc beneflt from the use of the Charlty of the Item Is probable and that economlc benefit can be measured rellably. (fj Exp•ndltur• & VAT Expendlture Is accounted for on an accruals basls and Is Incluslve of Irrecoverable VAT. Grants payable are charged to the Statement of Flnanclal Actlvltles when authorlsed by the Board of Trustee5 and communlcated to the reclplenL Charltable expendlture comprlses those costs Incurred by the Charlty In the dellvery of Its objectlves. It Includes both costs that can be allocated dlrectly to such actlvltles and the costs of an indlrect nature as necessary to support them. Costs of ralslng funds comprlse fundralslng costs and the costs Incurred In the subsldlary tradlng activities. Fundraislng costs Include advertlslng, produclng publlcatlons, prlnting and maillng fundralslng materlals, assoclated staff costs and an approprlate allocatlon of support costs. Support costs are those costs Incurred In support of the Charlty's prlmary objectlves and are allocated on the basls of staff tlme spent on those objectives. 37 Gynaecology Cancer Research Fund Annual Report Incorporatlng a Dlrectors. Report and Accounts the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 Governance costs are those costs relatlng to compllance wlth constftutlonal and statutory requlrements and the structure and governance revlew and are allocated on the basls of tlme spent overseelng the relevant actlvltles. (g) Tanglbl• Flx•d AM•ts and Deprnclatlon Tanglble Flxed assets are recorded at cost less depreclatlon and ImpalrmenL Depreclatlon Is provlded on all tanglble flxed assets In order to wrlte off thelr cost by equal annual Instalments over thelr expected useful Ilves. The rate adopted for Flxtures and Flttlngs @ 25% on cosL (h) Intanglbh Flx•d Asmts and Amortl•atlon Amortlsatlon Is provlded on all Intsnglble fixed assets In order to wrlte off thelr cost by equal annual Instalments over thelr expected useful Ilves. The rate adopted for trademarks @10% on cosL 111 Inv••tm•nts Unllsted Investments comprlse the followlng: _ Investments In subsldlarles whlch are measured at cost less Impalrment. Investments In a Jolnt venture acqulred In the year under revlew. Under the charlty SORP thls Is measured uslng the equlty method of accountlng. The equlty method of accountlng requlres the assoclate to be Inltlally recognlsed at Its cost (the transactlon prlce pald). Includlng any cost Incurred maklng the Investment (transactlon costs). Uslng the equlty method, the carrylng amount of an Investment In an assoclate Is subsequently adjusted through the SOFA to reflect the Investlng charlty's share of the assoclate's results. The carrylng amount thereby reflects the Investor's share of the post acqulsltlon change In the net assets of the assoclate. U) Stoek Stock prlnclpally conslsts of artwork donated by artlsts and Is valued at the lower of cost and net reallsable value. Artworks provlded by art15ts are recognlsed In the flnancl81 statements at thelr antlclpated sales prlce. less antlclpated cost of sales 8nd any subsequent Impalrment. (kl Cash and Cash Equlval•nts Cash at bank and In hand includes deposlts whlch can be wlthdrawn wlthln 24 hours wlthout penalty and short-term deposlts which have a maturty period of 4 months or less and are not subject to slgnlflcant rlsk of changes In value. (l) Tax Status Gynaecology Cancer Research Fund (Llmlted by Guarantee) Is a reglstered company, number 04370087 and Is exempt from corporatlon tsx under the provlslons of Sectlons 466-493 of the Corporation Taxes Act 2010. 38 Gynaecology Cancer Research F￿d Annual Rewt Incorporaong a Dlrectors. Report and AcC￿nts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 (m) Op•ratlng Lea￿5 Rentals payable under operatlng leases are charged to the Statement of Flnanclal Actlvftles as Incurred over the period of the lease on a stralght-llne basls. (n) P•n•lon• The Charlty operates a deflned contrlbutlon penslon scheme. The contrlbutlons to the deflned contrlbutlon scheme are charged to the Ststement of Flnanclal Actlvltles as they become payable. (•) Flnan¢lal Instrum•nts The Charlty only has financlal assets and flnancl81118bllltles of a klnd that quallfy as baslc flnanclal Instruments. Baslc flnanclal Instruments are Initlally recognlsed at transactlon value and subsequently measured at thelr settlement value. The Charlty does not have any bank loans, (p) Slgnllkant Accountlng Estlmat•s and Judg•m•nts EstSmates and Judgements are contlnually evaluated and are based on hlstorlcal experlence and other factors. Includlng expectatlons of future events that are belleved to be reasonable under the clrcumstances: (l) Glft• In klnd Glfts In klnds are recognlsed wlthln Incomlng resources and expendlture at an estlmate of the value to the Charlty of the donated servlces or goods. Where posslble the value of seNlceslgoods are conflrmed dlrectty wlth the suppller however In some Instances thls Informatlon Is not avallable and a best estlm8ted Is made of the expected cost of such goods based on whet the Charlty would be wllllng to pay for slmllar servlces or goods at a market rate. 39 Gynaecology Cancer Research Fund Annual Report Incorporallng a Olrectors. Report and Accourts for the year erKllng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 3. Ine¢)me: donatlon• and legacles 2024 Unrestrlcted Restrlcted 2023 Total Indlvldual glvlng Communlty Trust and foundatlons Major donors Corporate Legacles Glfts In klnd Totsl 335,650 376,039 48,632 20,524 230,527 28,866 190,772 1231010 14,494 26,462 274,370 66,250 6,000 40,000 350,144 402,501 323,002 86,774 236,527 68,866 190,772 427 576 1658 586 328.189 358.871 237.700 37,671 108,278 55.870 114 626 1241205 In 2024 £1,141,788 (2023: £880.855) of donatlon and legacles related to unrestrlcted funds and £427.576 (2023: £325,956) was attrlbut8ble to restrlcted funds. Income from donatlon and legacles Include donated serylces worth £190.77212023: £114.626) 4. Incom•: from tradlng actlvltl•s 2024 Unrestrlcted Restrlcted Total 2023 Communlty Tradlng subsldlary (see note 16) Totsl 101550 101550 101550 101550 40 Gynaecology Cancer Researth Fund Annual Report Inconxyatlng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 5. Ana￿19 of •xpondltur• Dlrect costs Support Governance costs cost Total 2024 Expendtture on ralslng funds (Notes 6,8.9} Expenditure on charitable activities {Notes 458.128 96.970 29.360 584,458 7,8,9) Charlty expendlture on ralslng funds Consolldated 960 614 105 299 31882 1097 795 1418 742 202 269 1418 742 202 269 61242 1682 253 61242 1682 253 Dlrect costs Support Governance costs cost Total 2023 Expendtture on ralslng funds (Note 6,8.9) Expendlture on charltable actlvltles (Note 7,8,9) Charlty expendlture on ralslng funds Consolldated 495.588 80,336 18,832 594,756 850 381 126 894 28 249 1005 524 1345 969 207 230 1345 969 207 230 47 081 1600 280 47 081 1600 280 Expendlture relatlng to ralslng funds In 2024 was £584,374 unrestrlcted (2023: £594,oon and £84 restrlcted (2023: £751). Expendlture on charltable actlvltles In 2024 was £662,812 unrestrlcted (2023: £667,337) Includlng donated serylces worth £190.772 (2023: £114,626) and £434,984 from restrlcted (2023: £338.187). Dlrect cost of generallng donatlons and legacles 2024 Restricted 2023 Unrestrlcted Total Indfvldual glvlng Communlty Trust and foundatlons Major donors Corporate Legacles Central Total 46,842 89,473 469 4.152 12,937 75 46,918 89.482 469 4,152 12,937 48.183 73,112 3,264 727 381 16,152 304,170 353,769 458.128 495 588 304 170 458.044 41 Annual Report Incorpornllng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 7. Dlr•ct costs of charltabl• actlvltle• 2024 Unrestrlcted Restrlcted 2023 Total Research grants (note 10) Ask Eve - Nurse-led Informatlon servlce Every Women Promlse- DHSC Informatlon and awareness Outreach Research Glfts In klnd Total 27.071 207,131 234,202 248,861 18,426 11,822 225,838 57,344 75,770 142.876 154,698 225,838 17,262 62,073 76,776 182,275 232,151 17,262 62.073 190 772 48,969 424 612 960 614 850 381 8, Dlr•ct c•sts of gov•rnanc• 2024 Unrestrlcted Restrlcted 2023 Total Group - audlt fees Group - non audlt fees Dlrectors Indemnlty Insurance Insurance Trustee costs Staff and contractor costs Other costs Total 17,256 6,832 2,869 17,256 6,832 2,869 16.679 1,157 1,356 72 27.738 79 77 33.785 423 33,785 423 g. Anaty￿S of support co•ts 2024 Unrestrlcted Restrlcted 2023 Total Rent. servlce charges and utllltles Insurance IT. phone, and Internet Stsff and contractor costs General corporate senilces Total 13.445 423 27.665 106,695 43,670 191898 2.239 15,684 423 34,286 106,695 13,644 306 35,245 139,282 18,753 207 230 6,621 10,371 202,269 42 Gynaecology Cancer Research Fund Annual Report In¢￿￿￿n0 a Dlrectors, Report and Accounts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 10. R•••arch grants award•d by In•lltutl¢)n In¢lud•d In Charltabh Artlvltl￿ wer• the followlng r•war¢h grant&" 2024 Restrlcted 2023 Unrestrlcted Total Unfverslty College London University of Birmingham AMRC Fellowshlp Ovarlan Cancer Rare Gynae BGCS Audlt Grant commltments reclalmed Total 22.250 17.750 40.000 167,026 89,700 44,249 56,126 89,006 44,249 56.126 90,948 5,000 1,942 5,000 207 131 234 202 248 861 11. Staff costs 2024 2023 Wages and salarles Soclal securlty Costs Staff penslon 718,591 70,230 722.297 69,819 820,518 819.769 Costs of contracts Total staff costs 865 455 891268 Total number of employees whose total employee benefits (excludlng employer penslon costs and employer natlonal Insurance contrlbutlons) amounted to over £60,000 In the year were: 2024 2023 £70.000 - £79,999 £80,000 - £89,999 £90,000 - £99.999 Average staff numbers: Charftable actfvltles Fundralslng and support 10 11 18 20 43 Gynaecology Cancer Research Fund Annual Report Incorpor8tlNJ a Dlrectors. Report and Accounts for the yew endlng 31 De￿rnber 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 The key management personnel of the parent charlty comprlses the Chlef Executlve, the Dlrector of Fundralslng, the Head of Programmes and the Head of Finance. The total employee beneflt of the key management personnel In the year were £309,683 (2023: £277.417). 12. Trust•M r•mun•ratlon and •xp•ns•s ol b•n•fft• In klnd None of the trustees recelved any remuneratlon durlng the year (2023: None). Durlng the year £2,869 {2023: £1,157) was pald In respect of trustees, Indemnlty Insurance. No trustees clalmed for any expenses durlng the year (2023: none). 13. N•t mov•m•nt In funds 2024 2023 Net movement In funds Is Stated after charglng: Audftors remuneratlon - current year Amortlsatlon Depreclatlon Amounts payable under operatlng leases: 17,256 799 8,662 15.579 799 8,011 Land and bulldlngs 38,433 46.747 44 Gynaecology Cancer Research Fund Annual Report Incorporatlng a Dlrectors. Report and Attounts for the yew endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 14. Intanglble flxed assets- Group and Charlty Trademarks Cost at 1° January 2024 7.988 Amortlsatlon: At 1" January 2024 Charge for the year At 31$1 December 2024 4,527 799 5,326 Net book value at 31" December 2024 Net book value at December 2023 15. Tanglbl• flx•d aM•ts Flttlng & Equlpment Cost: At 1st January 2024 Addltlons Dlsposal At 31st December 2024 113,038 1.288 33.450 Depreclatlon: At 1" January 2024 Charge for the year Depreclation on dlsposals At 31" December 2024 95,057 8,662 22,843 Net book value at 3V December 2024 Net book value at 3fl December 2023 45 Gynaecola9y Cancer Research Fund Annual Report Incorporallng a Dlreclws, Report arKI Accowbts ft•r the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 16. Inve•tments held as Ilxed assets - ¢harlty 2024 2023 Shares In subsidlary undertaklng at cost Shares In Jolnt Venture at falr value 7,432 Jolnt Venture The charlty has a share In Sola Dlagnostlcs GmBh, an Austrlan company. Shares (whlch wlll decrease over tlme) were glfted to the Charlty from Professor Martln Wldschwendter. The carrying amount of the Investment was £7.4318t the year end. whlch Is deemed to be Its falr value. Subsldlary The ch8rSty has wholly owned subsldlary Incorporated In England. Eve Appeal Llmlted, whlch ralses funds through activity Includlng cause related marketlng and sales of goods. The company pays its proflt under Glft Ald to the Gyn8ecologlcal Cancer Research Fund. A summary of Its tradlng results (Included wlth 'Other tradlng actlvftles.) for the perlod ended 31 December 2024 Is as follows: 2024 2023 Proflt and loss Turnover Admlnlstratlon expenses Net proflt before tax Taxatlon Net result Proflt and loss reserves Brought forward at 1st January Net result In perlod Dlstrlbutlon to Gynaecology Cancer Research Fund 101,550 2,940 104,490 87,901 85,631 104 490 85.631 104,490 26,653 85.631 104.490 Summary Balance Sheet Current assets Debtors Cash at bank and In hand Total current assets 74,845 30.715 105.560 28,339 115.759 Current Ilabllftles Creditors- amounts falllng due wlthln one year Net current assets Total assets less totsl Ilabllftles 1,069 104,491 104 491 30,129 85.630 Capltal and reserves Share capltal Profft and loss accounts Total 104.490 104 491 85.632 46 Annual Report IncorporallNJ 8 Dlrectors. Report and ACco￿ts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year End￿ 31 DeceM￿r 2024 Group Charlty 2024 2023 2024 2023 Trade debtors 65.696 34,239 22,337 5.896 Amount owed by group undertaklngs Prepayment and accrued Income Other debtors 18.181 133.053 2.472 201,221 146,163 133,053 2.471 157 861 146.163 191.025 180 863 18. Cr•dltor• Group Charlty 2024 2023 2024 2023 Grants payable Trade credltors Amount owed to group undertaklngs Accruals Taxatlon and soclal securlty Other credltors 447,286 16,363 418,838 15,631 447,286 9,625 38,223 24,820 418,838 9,021 25,888 20,450 15.250 1,251 160 1.250 20 499 679 530 095 19. Unvestrlcted funds- Group At1 January 2024 Income Expendlture At31 December 2024 General funds Emergency fund 182.326 180,000 362 326 1355 262 1.355,262 {1.247.186) 290,402 180 000 470 402 1,247,186 Emergency fund The reseNes pollcy for the charlty, as agreed by the Trustees, Is to malntsin a mlnlmum of three months budgeted expendlture, excludlng expenditure on research grants. Further Information on thls and the ratlonale for thls can be found In the reserves sectlon of the Trustees Report. 47 Gynaecology Cancer Research Fund Annual Report Incorporatlng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 Unrnstrkted funds . Charlty At1 January 2024 Income Expendlture At31 December 2024 General funds Emergency fund 96,697 180 000 276 697 1,339,342 (1,250,127) 185,912 180.000 365 912 1339 342 20. R￿trkt•d Fund•- Group At1 January 2024 Income Expendlture At31 December 2024 Ask Eve BRCA Research Vulval Cancer Awareness HPV Resources Rare Gynaecology Research Ovarlan Cancer Research UCL Strateglc Research Fundlng Every Women Promlse Outreach Fellowshlp 109,497 50 1.445 1,317 (57,427) (1) 52.070 16,044 1,445 79,410 678 15,995 78,093 678 66,167 60,245 12,750 66,886 18.587 60 319 461 427 576 22.840 99.057 6,000 143,121 (89,006) (56,126) (17,750) (153,247) (17,262) 44,249 435 068 103,176 1,000 56,760 1.325 60 311969 Restrlcted Funds: Ask Eve: The nurse let Informatlon servlce provldlng free, confldentlal, gynae Informatlon vla phone or emall. BRCA Research: Several of our research programmes have a strong focus on the BRCA gene mutatlon to early detect or prevent ovarlan and breast cancer - for example BRAC Project, BRCA UNITE and GCaPPS. Vulval Canc•r. Vufval cancer Is one of the rare gynaecologleal cancers wlth Just over 1,000 cases In the UK dlagnosed each year. Increased awareness of the signs and symptoms of vulval cancer are essential to ensure that women see thelr GP as soon as they notlce somethlng not rlght for them and to keep going back rf it continues. Gynaecology Cancer Resewch Fund Annual Rep￿ Incwratlng a Dlrectors. Report and Accounts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 Awaren￿. Thls fund Is restrlcted to ralsing awareness of gynaecologlcal cancers and communlcatlon work around certaln campalgns such as Gynae Cancer Awareness Month. HPV R•4ourcw' Thls project works to embed a deeper and more nuanced publlc understandlng of HPV. seelng to reduce dlsease rlsk, promote preventatlve behavioural change, and Improve patlent outcomes for HPV and related dlsease across the board. Rar• Gynaecologlcal Cancer Remarch: Less than 5% of the 21,000 women dlagnosed wlth gynaecologlcal cancer In the UK are dlagnosed wlth the rate form. The low number of new cases of these rare cancers mean Indlvldual doctors are unfamlllar wlth symptoms, too often resultlng In a late dlagnosls, wlth treatment that may not be optlmal for the dlsease type and subsequent progresslon of the dlsease. More research to advance and Improve the early dlagnosls and preventlon rare 9ynaecologlcal cancers. Ovarlan Can¢•r Rew4rch: In the UK nearty 7,500 people are dlagnosed wlth ovarian cancer every year. The symptoms are not always obvlous. and It Is often dlagnosed In a late state, Research Into early detectlon, rlsk predlctlon and preventlon Is needed. UCL Str•t•gk R•m)￿h Fundlng: Focuslng on Prof. Wldschwendter's research contlnulng at UCL. The Cllnlcal Assessment & work up of the WIDqEC test In women at hlght rlsk for Endometrl81 (Womb) Cancer. Every Women Prom1￿. Thls project supports and educates women In the workplace, to report symptoms and seeks advlce on gynaecologlcal health Issues and makes employers aware of the Issues. The alm Is to both Improve the health chances for each woman but to Improve to corporate envlronment, through engagement at a corporate ownershlp and management level. Outreach: Thls project addressed the dlsparltles In gynaecologlcal health outcomes among Black women by Improvlng awareness, access to Informatlon. and confldence In seeklng medlcal care for gynae cancers and overall health. Thls fundlng enabled us to dellver tallored educatlon, develop new partnershlps. and create sustalnable resources that wlll beneflt communltles beyond the Inltlal grant perlod. Follo￿h1￿ We appolnted our first Inaugural fellow: Dr Kelechl Njoku from the Unlverslty of Manchester, who Is using hls fellowship to develop a slmpler and klnder test for detecting womb cancer. We received a large grant from the AMRC towards thls programme. 49 Gynaecology Carbcer ReS￿r¢h Fund Annual Report Inc¢)rporallng a Dlrectors. Report and A£counts for the year endlng 31 December 2024 Notes to the Flnanclal Statements For the Year Ended 31 December 2024 21. Anatysls of N•t Asmts b•tw••n Funds. Group 2024 Restrfcted 2023 Unrestrlcted Totsl Flxed Assets Current Assets Credltors: amounts falllng due withln 1 year Total 20,700 949,381 20.700 311.969 1.261.350 28.873 1,119,920 499 679 470 402 499.679 782 371 311,969 681.787 22. L¢g81 Status •fth• C￿rIty The charity is limited by guarantee and therefore does not have share capltal. The Ilablllty of the members15 Ilmlted to the sum of £1 per member, and the number of members was 13 (2023: 13). 23. Uftlmat• Controlllng P•rty Eve Appeal Llmlted Is a wholly owned subsldlary of Gynaecology Cancer Research Fund, whlch Is the ultlmate controlllng party, The uttlmate controlllng paty of Gynaecology Cancer Research Fund are the Trustees, 24. R•lated Party Tran•artlon• Durlng the year under revlew, the charlty recelved Income totalllng £18,070 In donatlons from 9 Trustees, both current and reslgned In the perSod, Includlng partners (2023: £20,254 from 7 Trustees Includlng partners). Reed Smlth LLP provlded pro bono legal servlces and other support to the charlty totalllng £80.116 (2023: 14,989). Tamara Box, a partner at Reed Smlth LLP Is also chalr of board of trustee of the charlty. 25. Commltm•nts under operatlng leas The group and charlty had the followlng future mlnlmum lease payment under non-cancellable operatlng leases: Group Charlty 2024 2023 2024 2023 Land and bulldlng&" Wlthln one year Between one year and flve years 10,675 25,357 10,657 10.675 25.357 10,675 36,090 qulpment: Wlthln one year Between one year and flve years £840 £1,561 £840 Total Commltments £46 747 £38 433 50